When was AbSci founded?

AbSci was founded in 2011 and raised its 1st funding round 5 years after it was founded.

Where is AbSci located?

AbSci is headquartered in Vancouver, United States.

Who is the current CEO of AbSci?

Sean McClain of AbSci. They have also founded 1 company.

How many employees does AbSci have?

As of Sep 30, 2026, the latest employee count at AbSci is 160.

Is AbSci a funded company?

AbSci is a funded company, having raised a total of $228M across 7 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Apr 11, 2016.

When was the latest funding round of AbSci?

AbSci's latest funding was a $***** Series E round on Mar 23, 2021, with participation from 7 investors.

What is the annual revenue of AbSci?

Annual revenue of AbSci is between $1M and $10M as on Dec 31, 2025

Where does AbSci rank among its competitors?

AbSci ranks 5th amongst 20 active competitors, of which 10 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Chai Discovery, which secured $400M in Jul, 2026.

Who are the top competitors of AbSci?

AbSci's top competitors include Chai Discovery, Antiverse and Apoha. Among them, Chai Discovery secured the most recent funding round in July, 2026.

AbSci - 2026 Company Profile, Team, Funding, Competitors & Financials

AbSci is a public company based in Vancouver (United States), founded in 2011 by Sean McClain. It operates as a Developer of AI based technology for the production of recombinant protein for therapeutic applications. AbSci has raised $228M in funding from investors like Casdin Capital, AGC and Phoenix Venture Partners. The company has 20 active competitors, including 10 funded and 2 that have exited. Its top competitors include companies like Chai Discovery, Antiverse and Apoha.

Company Details

Developer of AI based technology for the production of recombinant protein for therapeutic applications. The company's integrated drug creation platform enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.

Website: absci.com
Social
Email ID: *****@abscibio.com
Phone Number: +1 **********

Key Metrics

Founded Year

2011

Location

Vancouver, United States

Stage

Public

Total Funding

$228M in 7 rounds

Latest Funding Round

Series E, Mar 23, 2021, $*****

Investors

Casdin Capital & 23 more

Ranked

5^th among 20 active competitors

Annual Revenue

$1M - $10M as on Dec 31, 2025

Employee Count

160 as on Sep 30, 2026

Investment & Acquisitions

Totient & 1 more

Similar Companies

Chai Discovery & 18 more

Exit Details

Public

View AbSci's full profile

AbSci is associated with 4 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Absci Corporation CIN: 6940491 , United States, Active	Jul 18, 2023	-	-	-
ABSCI CORP CIN: 1672688 , United States, Active	Oct 04, 2020	$1M - $10M (As on Dec 31, 2025)	-	-
Absci Corporation CIN: 853383487 , United States, Active	Dec 31, 1999	-	139 (As on Dec 31, 2024)	-
Absci, Llc CIN: 453931977 , United States, Active		$1M - $5M (As on Dec 18, 2019)	57 (As on Dec 31, 2020)	-

AbSci got listed on Jul 22, 2021.

Click here to take a look at AbSci's IPO in detail

AbSci has raised a total funding of $228M over 7 rounds. Its first funding round was on Apr 11, 2016. Its latest funding round was a Series E round on Mar 23, 2021 for $*****. 7 investors participated in its latest round. AbSci has 24 institutional investors.

Here is the list of recent funding rounds of AbSci:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 23, 2021	5292285	Series E	5735591	5156651	5050620	2587932
Oct 20, 2020	1392607	Series E	8781300	4151589	4061127	Redmile Group & 3 more
Jan 13, 2020	3015965	Conventional Debt	8490438	2022079	4298279	2942474

Access funding benchmarks and valuations. Sign up today!

View details of AbSci's funding rounds and investors

The founders of AbSci is Sean McClain. Sean McClain is the CEO of AbSci.

Here are the details of AbSci's key team members:

Sean McClain: Founder & CEO of AbSci and founder of 1 other company.
Contact Info: 1 email address

View details of AbSci's Founder profiles and Board Members

AbSci's employee count trend

AbSci has 160 employees as of Sep 26. Here is AbSci's employee count trend over the years:

Uncover AbSci's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of AbSci include Chai Discovery, Antiverse and Apoha. Here is the list of Top 10 competitors of AbSci, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Chai Discovery 2023, San Francisco (United States), Series C	Developer of artificial intelligence models for de novo molecular design	$630M	Kleiner Perkins, Oak HC/FT & 30 others	69/100
2nd	Antiverse 2017, Cardiff (United Kingdom), Series A	Developer of computational platform for de novo design of antibody therapeutics	$20M	Kadmos Capital, Cambridge Angels & 34 others	67/100
3rd	Apoha 2021, Bolton (United Kingdom), Series A	Developer of sensory intelligence software to seamlessly anchor machines into physical reality to understand and analyze material behavior	$36M	Singular, Draper & 6 others	60/100
4th	BigHat 2019, San Carlos (United States), Series B	Provider of antibody therapies developed by machine learning and synthetic biology	$148M	S32, Andreessen Horowitz & 13 others	58/100
5th	AbSci 2011, Vancouver (United States), Public	Developer of AI based technology for the production of recombinant protein for therapeutic applications	$228M	equitywestsecurities.com, ArrowMark Partners ... & 22 others	57/100
6th	LabGenius Therapeutics 2012, London (United Kingdom), Series B	Developer of an automated platform for therapeutic antibody discovery	$69.5M	Atomico, Obvious Ventures & 15 others	56/100
7th	BioGeometry 2022, Haidian (China), Seed	AI-driven platform developing next-generation programmable protein medicines	-	Jiangmen Ventures, Dachen Capital & 6 others	47/100
8th	Ordaos 2019, New York City (United States), Seed	Provider of an AI accelerator for biomedical research and drug discovery	$21.5M	VTC Ventures, IAG Capital Partners & 5 others	47/100
9th	immunitoAI 2020, Bengaluru (India), Series A	Developer of AI-based platform for antibody discovery and therapeutics	$7.98M	pi Ventures, C-CAMP & 31 others	43/100
10th	Oncimmune 2006, Cambridge (United States), Acquired	Immunodiagnostics company developing biomarker platforms for cancer and immune diseases	-	IPF Partners, WG Partners & 9 others	42/100